Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
10 "Young Seok Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
General
Radiation Oncologists’ Perspectives on Oligometastatic Disease: A Korean Survey Study
Chai Hong Rim, Won Kyung Cho, Jong Hoon Lee, Young Seok Kim, Yang-Gun Suh, Kyung Hwan Kim, Ah Ram Chang, Eui Kyu Chie, Yong Chan Ahn, on behalf of the Oligometastasis Working Group, Korean Cancer Association
Cancer Res Treat. 2024;56(2):414-421.   Published online November 22, 2023
DOI: https://doi.org/10.4143/crt.2023.876
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Perspectives of radiation oncologists on oligometastatic disease was investigated using multi-layered survey.
Materials and Methods
Online survey on the oligometastatic disease was distributed to the board-certified regular members of the Korean Society for Radiation Oncology. The questionnaire consisted of four domains: five questions on demographics; five on the definition of oligometastatic disease; four on the role of local therapy; and three on the oligometastatic disease classification, respectively.
Results
A total of 135 radiation oncologists participated in the survey. The median length of practice after board certification was 22.5 years (range, 1 to 44 years), and the vast majority (94.1%) answered affirmatively to the clinical experience in oligometastatic disease management. Nearly two-thirds of the respondents considered the number of involved organs as an independent factor in defining oligometastasis. Most frequently perceived upper limit on the numerical definition of oligometastasis was 5 (64.2%), followed by 3 (26.0%), respectively. Peritoneal and brain metastasis were nominated as the sites to be excluded from oligometastastic disease by 56.3% and 12.6% of the participants, respectively. Vast majority (82.1%) agreed on the role of local treatment in the management of oligometastatic disease. Majority (72%) of the participants acknowledged the European Society for Radiotherapy and Oncology (ESTRO)–European Organisation for Research and Treatment of Cancer (EORTC) classification of oligometastatic disease, however, only 43.3% answered that they applied this classification in their clinical practice. Underlying reasons against the clinical use were ‘too complicated’ (66.0%), followed by ‘insufficient supporting evidence’ (30.0%), respectively.
Conclusion
While most radiation oncologists supported the role of local therapy in oligometastatic disease, there were several inconsistencies in defining and categorizing oligometastatic disease. Continued education and training on oligometastatic disease would be also required to build consensus among participating caregivers.

Citations

Citations to this article as recorded by  
  • Efficacy Analysis of Hypofractionated Radiotherapy for Oligometastatic Tumors: A Retrospective Study
    Qian Sun, Hanqing Zhao, Xianwen Zhang, Suli Zhang, Zelai He, Gengming Wang, Hao Jiang, Aili Xuan, Xianming Li
    Technology in Cancer Research & Treatment.2025;[Epub]     CrossRef
  • ‘Perspectives of pulmonologists and thoracic surgeons on Oligometastatic disease: curability, treatment approaches, and disease trajectory’
    Damla Azaklı, Inanc Yazici, Aysegul Erinc, Celal Satici
    Future Oncology.2025; : 1.     CrossRef
  • Expert consensus on radiotherapy for oligometastatic esophageal cancer (2025 edition)
    Zhiguo Zhou, Xiaoyan Lv, Jun Wang, Zhouguang Hui, Qingsong Pang
    Radiation Medicine and Protection.2025;[Epub]     CrossRef
  • A new proposal of simplified classification of non-small cell lung cancer oligometastases for easy applicability through systematic literature analysis and meta-analysis validation
    Hanseung Kang, Woohyeon Do, Yong Chan Ahn, Eui Kyu Chie, Chai Hong Rim
    European Journal of Cancer.2024; 212: 115043.     CrossRef
  • 3,312 View
  • 153 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis
Chai Hong Rim, Won Kyung Cho, Jong Hoon Lee, Young Seok Kim, Yang-Gun Suh, Kyung Hwan Kim, Eui Kyu Chie, Yong Chan Ahn, The Oligometastasis Working Group, Korea Cancer Association
Cancer Res Treat. 2022;54(4):953-969.   Published online August 16, 2022
DOI: https://doi.org/10.4143/crt.2022.329
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We intend to investigate the oncological efficacy and feasibility of local consolidative therapy (LCT) through a meta-analysis method.
Materials and Methods
Four databases including PubMed, MEDLINE, Embase, and Cochrane library were searched. Target studies are controlled trials comparing outcomes of LCT versus a control group. Primary endpoints are overall survival (OS) and progression-free survival (PFS).
Results
A total of 54 studies involving 7,242 patients were included. Pooled analyses showed that the LCT arm could achieve improved OS with pooled odds ratio of 2.896 (95% confidence interval [CI], 2.377 to 3.528; p < 0.001). Regarding PFS, pooled analyses showed pooled odds ratio of 3.045 (95% CI, 2.356 to 3.937; p < 0.001) in favor of the LCT arm. In the subgroup analyses including the studies with reliable comparability (e.g. randomized studies or intentionally matched studies without significant favorable prognosticator in LCT arms), pooled odds ratio was 2.548 (95% CI, 1.808 to 3.591; p < 0.001) favoring the LCT arm regarding OS. Regarding PFS, pooled OR was 2.656 (95% CI, 1.713 to 4.120; p < 0.001) which also favored the LCT arm. Subgroup analyses limited to the randomized controlled trials (RCT) were also performed and pooled odds ratios on OS and PFS were 1.535 (95% CI, 1.082 to 2.177; p=0.016) and 1.668 (95% CI, 1.187 to 2.344; p=0.003). The rates of grade ≥ 3 complications related to LCT was mostly low (< 10%) and not significantly higher compared to the control arm.
Conclusion
Pooled analyses results of all included studies, selected studies with reliable comparability, and RCT’s demonstrated the survival benefit of LCT. These consistent results suggest that LCT was beneficial to the patients with oligometastasis.

Citations

Citations to this article as recorded by  
  • Identifying Trends in Oncology Research through a Bibliographic Analysis of Cancer Research and Treatment
    Choong-kun Lee, Jeong Min Choo, Yong Chan Ahn, Jin Kim, Sun Young Rha, Chai Hong Rim
    Cancer Research and Treatment.2025; 57(1): 11.     CrossRef
  • The Society of Thoracic Surgeons (STS) Clinical Practice Guideline on Surgical Management of Oligometastatic Non-small Cell Lung Cancer
    Mara B. Antonoff, Kyle G. Mitchell, Samuel S. Kim, Hai V. Salfity, Svetlana Kotova, Robert Taylor Ripley, Alfonso L. Neri, Pallavi Sood, Saumil G. Gandhi, Yasir Y. Elamin, Jessica S. Donington, David R. Jones, Elizabeth A. David, Stephen G. Swisher, Isabe
    The Annals of Thoracic Surgery.2025; 119(3): 495.     CrossRef
  • Maintaining First-Line Therapy Plus Radiation Therapy May Prolong Progression-Free Survival and Delay Second-Line Therapy for Oligoprogressive Hepatocellular Carcinoma
    Boyu Leng, Haohua Wang, Yunfan Ge, Xiaoli Sun, Pingping Dong, Xinzhe Dong, Xuezhang Duan, Quan Wang, Yaoxiong Xia, Lijuan Ding, Honghai Dai, Tianxing Liu, Fang Shi, Xiang Zhang, Jinbo Yue
    International Journal of Radiation Oncology*Biology*Physics.2025; 122(2): 325.     CrossRef
  • The patterns of systemic metastasis in major salivary gland cancer and therapeutic implications
    Subi Oh, Younghac Kim, Hyojun Kim, Eunhye Kim, Sook-young Woo, Nayeon Choi, Junhun Cho, Dongryul Oh, Yong-Chan Ahn, Sehhoon Park, Myung-Ju Ahn, Han-Sin Jeong
    Oral Oncology.2025; 164: 107258.     CrossRef
  • Surgery for Stage IV Disease—Is It Prime Time Yet?
    Marianna V. Papageorge, Mara B. Antonoff
    Surgical Oncology Clinics of North America.2025;[Epub]     CrossRef
  • Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma
    Gowoon Yang, Kyung Hwan Kim, Chang Geol Lee, Min Hee Hong, Hye Ryun Kim, Yeona Cho, Hong In Yoon
    Cancer Research and Treatment.2024; 56(1): 115.     CrossRef
  • MR-guided stereotactic radiotherapy of infra-diaphragmatic oligometastases: Evaluation of toxicity and dosimetric parameters
    Mette van Overeem Felter, Pia Krause Møller, Mirjana Josipovic, Susanne Nørring Bekke, Uffe Bernchou, Eva Serup-Hansen, Kasper Madsen, Parag J. Parikh, Joshua Kim, Poul Geertsen, Claus P. Behrens, Ivan R. Vogelius, Mette Pøhl, Tine Schytte, Gitte Fredberg
    Radiotherapy and Oncology.2024; 192: 110090.     CrossRef
  • Clinical implication of neck dissection for metastatic lymph nodes originating from non-head and neck regions
    Min Ji Kim, So Hee Kang, MinSu Kwon, Young Ho Jung, Seung-Ho Choi, Soon Yuhl Nam, Yoon Se Lee
    Acta Oto-Laryngologica.2024; 144(2): 153.     CrossRef
  • Surgery for Oligometastatic Pancreatic Cancer: Defining Biologic Resectability
    Shruti Koti, Lyudmyla Demyan, Gary Deutsch, Matthew Weiss
    Annals of Surgical Oncology.2024; 31(6): 4031.     CrossRef
  • Radiation Oncologists’ Perspectives on Oligometastatic Disease: A Korean Survey Study
    Chai Hong Rim, Won Kyung Cho, Jong Hoon Lee, Young Seok Kim, Yang-Gun Suh, Kyung Hwan Kim, Ah Ram Chang, Eui Kyu Chie, Yong Chan Ahn
    Cancer Research and Treatment.2024; 56(2): 414.     CrossRef
  • Radiation Oncologists’ Perspectives on Oligometastatic Prostate Cancer: A Survey from Korean Oligometastasis Working Group
    Gyu Sang Yoo, Sunmin Park, Chai Hong Rim, Won Kyung Cho, Ah Ram Chang, Young Seok Kim, Yong Chan Ahn, Eui Kyu Chie
    Current Oncology.2024; 31(6): 3239.     CrossRef
  • Local Ablative Therapy Combined With Pembrolizumab in Patients With Synchronous Oligometastatic Non-Small Cell Lung Cancer: A Recursive Partitioning Analysis
    Hye In Lee, Eun Kyung Choi, Su Ssan Kim, Young Seob Shin, Junhee Park, Chang-Min Choi, Shinkyo Yoon, Hyeong Ryul Kim, Young Hyun Cho, Si Yeol Song
    International Journal of Radiation Oncology*Biology*Physics.2024; 120(3): 698.     CrossRef
  • Retrospective Analysis of Efficacy and Toxicity of Stereotactic Body Radiotherapy and Surgical Resection of Adrenal Metastases from Solid Tumors
    Jamie Lütscher, Hans Gelpke, Adrian Zehnder, Laetitia Mauti, Christian Padevit, Hubert John, Nidar Batifi, Daniel Rudolf Zwahlen, Robert Förster, Christina Schröder
    Cancers.2024; 16(15): 2655.     CrossRef
  • A new proposal of simplified classification of non-small cell lung cancer oligometastases for easy applicability through systematic literature analysis and meta-analysis validation
    Hanseung Kang, Woohyeon Do, Yong Chan Ahn, Eui Kyu Chie, Chai Hong Rim
    European Journal of Cancer.2024; 212: 115043.     CrossRef
  • Oligometastasis: More Lessons to Be Learned
    Kyung Hwan Kim, Yong Chan Ahn
    Cancer Research and Treatment.2023; 55(1): 1.     CrossRef
  • Top Ten Lessons Learned from Trials in Oligometastatic Cancers
    Vivian S. Tan, David A. Palma
    Cancer Research and Treatment.2023; 55(1): 5.     CrossRef
  • Genomic Characteristics and the Potential Clinical Implications in Oligometastatic Non–Small Cell Lung Cancer
    Rongxin Liao, Kehong Chen, Jinjin Li, Hengqiu He, Guangming Yi, Mingfeng Huang, Rongrong Chen, Lu Shen, Xiaoyue Zhang, Zaicheng Xu, Zhenzhou Yang, Yuan Peng
    Cancer Research and Treatment.2023; 55(3): 814.     CrossRef
  • Metastasis-Directed Local Therapy of Hepatic Oligometastasis from Colorectal Cancer and Future Perspective in Radiation Therapy
    Gyu Sang Yoo, Chai Hong Rim, Won Kyung Cho, Jae-Uk Jeong, Eui Kyu Chie, Hyeon-Min Cho, Jun Won Um, Yong Chan Ahn, Jong Hoon Lee
    Cancer Research and Treatment.2023; 55(3): 707.     CrossRef
  • Barriers in Oligometastasis Care in Korea: Radiation Oncologists’ Perspectives
    Eui Kyu Chie, Chai Hong Rim, Won Kyung Cho, Yong Chan Ahn
    Cancer Research and Treatment.2023; 55(4): 1063.     CrossRef
  • Impact of high dose radiotherapy for breast tumor in locoregionally uncontrolled stage IV breast cancer: a need for a risk-stratified approach
    Nalee Kim, Haeyoung Kim, Won Park, Won Kyung Cho, Tae Gyu Kim, Young-Hyuck Im, Jin Seok Ahn, Yeon Hee Park, Ji-Yeon Kim
    Radiation Oncology.2023;[Epub]     CrossRef
  • Oligometastasis: Expansion of Curative Treatments in the Field of Oncology
    Ah Reum Lim, Chai Hong Rim
    Medicina.2023; 59(11): 1934.     CrossRef
  • Treating Oligometastses, Prelude or Just Hassles of Systemic Treatment
    Dae Ho Lee
    Cancer Research and Treatment.2022; 54(4): 951.     CrossRef
  • 7,318 View
  • 344 Download
  • 22 Web of Science
  • 22 Crossref
Close layer
Genitourinary cancer
Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer
Sung Uk Lee, Jae-Sung Kim, Young Seok Kim, Jaeho Cho, Seo Hee Choi, Taek-Keun Nam, Song Mi Jeong, Youngkyong Kim, Youngmin Choi, Dong Eun Lee, Won Park, Kwan Ho Cho
Cancer Res Treat. 2022;54(4):1191-1199.   Published online December 7, 2021
DOI: https://doi.org/10.4143/crt.2021.985
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study proposed the optimal definition of biochemical recurrence (BCR) after salvage radiotherapy (SRT) following radical prostatectomy for prostate cancer.
Materials and Methods
Among 1,117 patients who had received SRT, data from 205 hormone-naïve patients who experienced post-SRT prostate-specific antigen (PSA) elevation were included in a multi-institutional database. The primary endpoint was to determine the PSA parameters predictive of distant metastasis (DM). Absolute serum PSA levels and the prostate-specific antigen doubling time (PSA-DT) were adopted as PSA parameters.
Results
When BCR was defined based on serum PSA levels ranging from 0.4 ng/mL to nadir+2.0 ng/mL, the 5-year probability of DM was 27.6%-33.7%. The difference in the 5-year probability of DM became significant when BCR was defined as a serum PSA level of 0.8 ng/ml or higher (1.0-2.0 ng/mL). Application of a serum PSA level of ≥ 0.8 ng/mL yielded a c-index value of 0.589. When BCR was defined based on the PSA-DT, the 5-year probability was 22.7%-39.4%. The difference was significant when BCR was defined as a PSA-DT ≤ 3 months and ≤ 6 months. Application of a PSA-DT ≤ 6 months yielded the highest c-index (0.660). These two parameters complemented each other; for patients meeting both PSA parameters, the probability of DM was 39.5%-44.5%; for those not meeting either parameter, the probability was 0.0%-3.1%.
Conclusion
A serum PSA level > 0.8 ng/mL was a reasonable threshold for the definition of BCR after SRT. In addition, a PSA-DT ≤ 6 months was significantly predictive of subsequent DM, and combined application of both parameters enhanced predictability.

Citations

Citations to this article as recorded by  
  • New Prostate MRI Scoring Systems (PI-QUAL, PRECISE, PI-RR, and PI-FAB): AJR Expert Panel Narrative Review
    Adriano B. Dias, Silvia D. Chang, Fiona M. Fennessy, Soleen Ghafoor, Sangeet Ghai, Valeria Panebianco, Andrei S. Purysko, Francesco Giganti
    American Journal of Roentgenology.2025;[Epub]     CrossRef
  • Biochemical recurrence after radical prostatectomy and postoperative radiotherapy: current evidence and controversial issues
    Mattia Longoni, Fabian Falkenbach, Markus Graefen, Tobias Maurer, Pierre I. Karakiewicz, Francesco Montorsi, Alberto Briganti, Giorgio Gandaglia
    Current Opinion in Urology.2025;[Epub]     CrossRef
  • A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer
    Laura Evangelista, Fabio Zattoni, Marta Burei, Daniele Bertin, Eugenio Borsatti, Tanja Baresic, Mohsen Farsad, Emanuela Trenti, Mirco Bartolomei, Stefano Panareo, Luca Urso, Giuseppe Trifirò, Elisabetta Brugola, Franca Chierichetti, Davide Donner, Lucia S
    Journal of Nuclear Medicine.2024; 65(7): 1013.     CrossRef
  • Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer
    Inki Lee, Min Hwan Kim, Kyongkyu Lee, Keumrok Oh, Hyunwoo Lim, Jae Hun Ahn, Yong Jin Lee, Gi Jeong Cheon, Dae Yoon Chi, Sang Moo Lim
    Diagnostics.2023; 13(16): 2649.     CrossRef
  • 6,996 View
  • 180 Download
  • 3 Web of Science
  • 4 Crossref
Close layer
Special Article
Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea
Jii Bum Lee, Minkyu Jung, June Hyuk Kim, Bo Hyun Kim, Yeol Kim, Young Seok Kim, Byung Chang Kim, Jin Kim, Sung Ho Moon, Keon-Uk Park, Meerim Park, Hyeon Jin Park, Sung Hoon Sim, Hong Man Yoon, Soo Jung Lee, Eunyoung Lee, June Young Chun, Youn Kyung Chung, So-Youn Jung, Jinsoo Chung, Eun Sook Lee, Hyun Cheol Chung, Tak Yun, Sun Young Rha
Cancer Res Treat. 2021;53(2):323-329.   Published online March 15, 2021
DOI: https://doi.org/10.4143/crt.2020.1256
AbstractAbstract PDFPubReaderePub
At the end of 2019, the cause of pneumonia outbreaks in Wuhan, China, was identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In February 2020, the World Health Organization named the disease cause by SARS-CoV-2 as coronavirus disease 2019 (COVID-19). In response to the pandemic, the Korean Cancer Association formed the COVID-19 task force to develop practice guidelines. This special article introduces the clinical practice guidelines for cancer patients which will help oncologists best manage cancer patients during the COVID-19 pandemic.

Citations

Citations to this article as recorded by  
  • The impact of COVID-19 on clinical practices of colorectal cancer in South Korea
    Kwang Woo Kim, Hyoun Woo Kang
    Intestinal Research.2025; 23(1): 6.     CrossRef
  • Preoperative COVID-19 and Postoperative Mortality in Cancer Surgery: A South Korean Nationwide Study
    Jae-Woo Ju, Soo-Hyuk Yoon, Tak Kyu Oh, Ho-Jin Lee
    Annals of Surgical Oncology.2024; 31(10): 6394.     CrossRef
  • Impact of the COVID-19 Pandemic on Esophagogastroduodenoscopy and Gastric Cancer Claims in South Korea: A Nationwide, Population-Based Study
    Min Ah Suh, Su Bee Park, Min Seob Kwak, Jin Young Yoon, Jae Myung Cha
    Yonsei Medical Journal.2023; 64(9): 549.     CrossRef
  • The elderly population are more vulnerable for the management of colorectal cancer during the COVID-19 pandemic: a nationwide, population-based study
    Hong Sun Kang, Seung Hoon Jeon, Su Bee Park, Jin Young Youn, Min Seob Kwak, Jae Myung Cha
    Intestinal Research.2023; 21(4): 500.     CrossRef
  • Impact of Coronavirus Disease 2019 on Gastric Cancer Diagnosis and Stage: A Single-Institute Study in South Korea
    Moonki Hong, Mingee Choi, JiHyun Lee, Kyoo Hyun Kim, Hyunwook Kim, Choong-Kun Lee, Hyo Song Kim, Sun Young Rha, Gyu Young Pih, Yoon Jin Choi, Da Hyun Jung, Jun Chul Park, Sung Kwan Shin, Sang Kil Lee, Yong Chan Lee, Minah Cho, Yoo Min Kim, Hyoung-Il Kim,
    Journal of Gastric Cancer.2023; 23(4): 574.     CrossRef
  • Health-Seeking Behavior Returning to Normalcy Overcoming COVID-19 Threat in Breast Cancer
    Eun-Gyeong Lee, Yireh Han, Dong-Eun Lee, Hyeong-Gon Moon, Hyoung Won Koh, Eun-Kyu Kim, So-Youn Jung
    Cancer Research and Treatment.2023; 55(4): 1222.     CrossRef
  • Adherence to Physical Distancing and Health Beliefs About COVID-19 Among Patients With Cancer
    Sajida Fawaz Hammoudi, Oli Ahmed, Hoyoung An, Youjin Hong, Myung Hee Ahn, Seockhoon Chung
    Journal of Korean Medical Science.2023;[Epub]     CrossRef
  • To overcome medical gap in screening and surveillance of colorectal cancer during the COVID-19 pandemic
    Yoo Min Han
    Intestinal Research.2023; 21(4): 418.     CrossRef
  • COVID-19 pandemic: a new cause of unplanned interruption of radiotherapy in breast cancer patients
    Shiho Lee, Jaesung Heo
    Medical Oncology.2022;[Epub]     CrossRef
  • Impact of the COVID-19 Pandemic on Breast Cancer Management in Portugal: A Cross-Sectional Survey-Based Study of Medical Oncologists
    Diogo Alpuim Costa, José Guilherme Gonçalves Nobre, João Paulo Fernandes, Marta Vaz Batista, Ana Simas, Carolina Sales, Helena Gouveia, Leonor Abreu Ribeiro, Andreia Coelho, Margarida Brito, Mariana Inácio, André Cruz, Mónica Mariano, Joana Savva-Bordalo,
    Oncology and Therapy.2022; 10(1): 225.     CrossRef
  • Organisation of cancer care in troubling times: A scoping review of expert guidelines and their implementation during the COVID-19 pandemic
    Brenda Bogaert, Victoria Buisson, Zizis Kozlakidis, Pierre Saintigny
    Critical Reviews in Oncology/Hematology.2022; 173: 103656.     CrossRef
  • Surgical safety in the COVID-19 era: present and future considerations
    Young Il Kim, In Ja Park
    Annals of Surgical Treatment and Research.2022; 102(6): 295.     CrossRef
  • Effect of Cancer-Related Dysfunctional Beliefs About Sleep on Fear of Cancer Progression in the Coronavirus Pandemic
    Harin Kim, Inn-Kyu Cho, Dongin Lee, Kyumin Kim, Joohee Lee, Eulah Cho, C. Hyung Keun Park, Seockhoon Chung
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Impact of the COVID-19 Pandemic on Gastric Cancer Screening in South Korea: Results From the Korean National Cancer Screening Survey (2017–2021)
    Kyeongmin Lee, Mina Suh, Jae Kwan Jun, Kui Son Choi
    Journal of Gastric Cancer.2022; 22(4): 297.     CrossRef
  • Changes in cancer screening before and during COVID‐19: findings from the Korean National Cancer Screening Survey 2019 and 2020
    Thao Thi Kim Trinh, Yun Yeong Lee, Mina Suh, Jae Kwan Jun, Kui Son Choi
    Epidemiology and Health.2022; 44: e2022051.     CrossRef
  • Treatment decision for cancer patients with fever during the coronavirus disease 2019 (COVID-19) pandemic
    In Hee Lee, Sung Ae Koh, Soo Jung Lee, Sun Ah Lee, Yoon Young Cho, Ji Yeon Lee, Jin Young Kim
    Yeungnam University Journal of Medicine.2021; 38(4): 344.     CrossRef
  • 9,924 View
  • 248 Download
  • 15 Web of Science
  • 16 Crossref
Close layer
Original Articles
Clinical Outcomes of Postoperative Radiotherapy Following Radical Prostatectomy in Patients with Localized Prostate Cancer: A Multicenter Retrospective Study (KROG 18-01) of a Korean Population
Sung Uk Lee, Kwan Ho Cho, Won Park, Won Kyung Cho, Jae-Sung Kim, Chan Woo Wee, Young Seok Kim, Jin Ho Kim, Taek-Keun Nam, Jaeho Cho, Song Mi Jeong, Youngkyong Kim, Su Jung Shim, Youngmin Choi, Jun-Sang Kim
Cancer Res Treat. 2020;52(1):167-180.   Published online June 25, 2019
DOI: https://doi.org/10.4143/crt.2019.126
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
The purpose of this study was to investigate the clinical outcomes of postoperative radiotherapy (PORT) patients who underwent radical prostatectomy for localized prostate cancer.
Materials and Methods
Localized prostate cancer patients who received PORT after radical prostatectomy between 2001 and 2012 were identified retrospectively in a multi-institutional database. In total, 1,117 patients in 19 institutions were included. Biochemical failure after PORT was defined as prostate-specific antigen (PSA) ≥ nadir+2 after PORT or initiation of androgen deprivation therapy (ADT) for increasing PSA regardless of its value.
Results
Ten-year biochemical failure-free survival, clinical failure-free survival, distant metastasisfree survival, overall survival (OS), and cause-specific survival were 60.5%, 76.2%, 84.4%, 91.1%, and 96.6%, respectively, at a median of 84 months after PORT. Pre-PORT PSA ≤ 0.5 ng/ml and Gleason’s score ≤ 7 predicted favorable clinical outcomes, with 10-year OS rates of 92.5% and 94.1%, respectively. The 10-year OS rate was 82.7% for patients with a PSA > 1.0 ng/mL and 86.0% for patients with a Gleason score of 8-10. The addition of longterm ADT (≥ 12 months) to PORT improved OS, particularly in those with a Gleason score of 8-10 or ≥ T3b.
Conclusion
Clinical outcomes of PORT in a Korean prostate cancer population were very similar to those in Western countries. Lower Gleason score and serum PSA level at the time of PORT were significantly associated with favorable outcomes. Addition of long-term ADT (≥ 12 months) to PORT should be considered, particularly in unfavorable risk patients with Gleason scores of 8-10 or ≥ T3b.

Citations

Citations to this article as recorded by  
  • Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer
    Sung Uk Lee, Jae-Sung Kim, Young Seok Kim, Jaeho Cho, Seo Hee Choi, Taek-Keun Nam, Song Mi Jeong, Youngkyong Kim, Youngmin Choi, Dong Eun Lee, Won Park, Kwan Ho Cho
    Cancer Research and Treatment.2022; 54(4): 1191.     CrossRef
  • A discussion on controversies and ethical dilemmas in prostate cancer screening
    Satish Chandra Mishra
    Journal of Medical Ethics.2021; 47(3): 152.     CrossRef
  • Clinical Outcome of Salvage Radiotherapy for Locoregional Clinical Recurrence After Radical Prostatectomy
    Sung Uk Lee, Kwan Ho Cho, Jin Ho Kim, Young Seok Kim, Taek-Keun Nam, Jae-Sung Kim, Jaeho Cho, Seo Hee Choi, Su Jung Shim, Jin Hee Kim, Ah Ram Chang
    Technology in Cancer Research & Treatment.2021;[Epub]     CrossRef
  • 8,276 View
  • 210 Download
  • 3 Web of Science
  • 3 Crossref
Close layer
The Prognostic Impact of the Number of Metastatic Lymph Nodes and a New Prognostic Scoring System for Recurrence in Early-Stage Cervical Cancer with High Risk Factors: A Multicenter Cohort Study (KROG 15-04)
Jeanny Kwon, Keun-Young Eom, Young Seok Kim, Won Park, Mison Chun, Jihae Lee, Yong Bae Kim, Won Sup Yoon, Jin Hee Kim, Jin Hwa Choi, Sei Kyung Chang, Bae Kwon Jeong, Seok Ho Lee, Jihye Cha
Cancer Res Treat. 2018;50(3):964-974.   Published online October 24, 2017
DOI: https://doi.org/10.4143/crt.2017.346
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We aimed to assess prognostic value of metastatic pelvic lymph node (mPLN) in early-stage cervical cancer treated with radical surgery followed by postoperative chemoradiotherapy. Also, we sought to define a high-risk group using prognosticators for recurrence.
Materials and Methods
A multicenter retrospective study was conducted using the data from 13 Korean institutions from 2000 to 2010. A total of 249 IB-IIA patients with high-risk factors were included. We evaluated distant metastasis-free survival (DMFS) and disease-free survival (DFS) in relation to clinicopathologic factors including pNstage, number of mPLN, lymph node (LN)ratio (number of positive LN/number of harvested LN), and log odds of mPLNs (log(number of positive LN+0.5/number of negative LN+0.5)).
Results
In univariate analysis, histology (squamous cell carcinoma [SqCC] vs. others), lymphovascular invasion (LVI), number of mPLNs (≤ 3 vs. > 3), LN ratio (≤ 17% vs. > 17%), and log odds of mPLNs (≤ ‒0.58 vs. > ‒0.58) were significant prognosticators for DMFS and DFS. Resection margin involvement only affected DFS. No significant survival difference was observed between pN0 patients and patients with 1-3 mPLNs. Multivariate analysis revealed that mPLN > 3, LVI, and non-SqCC were unfavorable index for both DMFS (p < 0.001, p=0.020, and p=0.031, respectively) and DFS (p < 0.001, p=0.017, and p=0.001, respectively). A scoring system using these three factors predicts risk of recurrence with relatively high concordance index (DMFS, 0.69; DFS, 0.71).
Conclusion
mPLN > 3 in early-stage cervical cancer affects DMFS and DFS. A scoring system using mPLNs > 3, LVI, and non-SqCC could stratify risk groups of recurrence in surgically resected early-stage cervix cancer with high-risk factors.

Citations

Citations to this article as recorded by  
  • Should all cervical cancer patients with positive lymph node receive definitive radiotherapy: a population-based comparative study
    Yang Wang, Xingyu Liu, Jing Liu, Liying Liu, Yue Ma
    Archives of Gynecology and Obstetrics.2025; 311(1): 123.     CrossRef
  • Current Paradigm and Future Directions in the Management of Nodal Disease in Locally Advanced Cervical Cancer
    Elki Sze-Nga Cheung, Philip Yuguang Wu
    Cancers.2025; 17(2): 202.     CrossRef
  • Spectral computed tomography in the assessment of metastatic lymph nodes in cervical cancer patients treated with definitive radiotherapy: a single-center, prospective study
    Zheng Zeng, Yining Chen, Yuliang Sun, Bing Zhou, Haoran Xu, Lei He, Ke Hu, Jie Qiu, Fuquan Zhang, Junfang Yan
    Clinical & Experimental Metastasis.2025;[Epub]     CrossRef
  • A Hybrid Model-Based Clinicopathological Features and Radiomics Based on Conventional MRI for Predicting Lymph Node Metastasis and DFS in Cervical Cancer
    Mingke Tian, Fengying Qin, Xinyan Sun, Huiting Pang, Tao Yu, Yue Dong
    Journal of Imaging Informatics in Medicine.2025;[Epub]     CrossRef
  • Risk stratification of node-positive early-stage cervical cancer treated with radical hysterectomy followed by chemoradiotherapy: a retrospective single-center study
    Shuang-Zheng Jia, Duan Yang, Xue-Jiao Yang, Rui Wang, Xi Yang, Man-Ni Huang, Ju-Sheng An
    Radiation Oncology.2025;[Epub]     CrossRef
  • Significance of tumor size and number of positive nodes in patients with FIGO 2018 stage IIIC1 cervical cancer
    Michihide Maeda, Seiji Mabuchi, Mina Sakata, Satoki Deguchi, Reisa Kakubari, Shinya Matsuzaki, Tsuyoshi Hisa, Shoji Kamiura
    Japanese Journal of Clinical Oncology.2024; 54(2): 146.     CrossRef
  • Internal Validation of Predictive Models for Recurrence-Free Survival and Risk of Recurrence in Patients with Figo Stages I–IV Cervical Cancer
    Jorge Cea García, Francisco Márquez Maraver, M. Carmen Rubio Rodríguez, Laura Ríos-Pena, Inmaculada Rodríguez Jiménez
    Indian Journal of Gynecologic Oncology.2024;[Epub]     CrossRef
  • Prediction of recurrence-related factors for patients with early-stage cervical cancer following radical hysterectomy and adjuvant radiotherapy
    Gui-Fen Ma, Gen-Lai Lin, Si-Tong Wang, Ya-Yu Huang, Chun-Li Xiao, Jing Sun, Ting-Yan Shi, Li-Bing Xiang
    BMC Women's Health.2024;[Epub]     CrossRef
  • Based on 3D-PDU and clinical characteristics nomogram for prediction of lymph node metastasis and lymph-vascular space invasion of early cervical cancer preoperatively
    Shuang Dong, Yan-Qing Peng, Ya-Nan Feng, Xiao-Ying Li, Li-Ping Gong, Shuang Zhang, Xiao-Shan Du, Li-Tao Sun
    BMC Women's Health.2024;[Epub]     CrossRef
  • Predictive value of number of metastatic lymph nodes and lymph node ratio for prognosis of patients with FIGO 2018 stage IIICp cervical cancer: a multi-center retrospective study
    Yanna Ye, Rui Lian, Zhiqiang Li, Xiaolin Chen, Yahong Huang, Jilong Yao, Anwei Lu, Jinghe Lang, Ping Liu, Chunlin Chen
    BMC Cancer.2024;[Epub]     CrossRef
  • Prognostic Factors for Cervical Cancer in Asian Populations: A Scoping Review of Research From 2013 to 2023
    Syed S Abrar, Seoparjoo Azmel Mohd Isa, Suhaily Mohd Hairon, Najib M Yaacob, Mohd Pazudin Ismail
    Cureus.2024;[Epub]     CrossRef
  • New Classification of Tumor Microvessels and the Risk of Regional Metastasis in Squamous Cell and Glandular Cancers
    Marina Senchukova
    American Journal of Clinical and Experimental Medicine.2024; 12(5): 61.     CrossRef
  • Analysis of prognostic factors for cervical mucinous adenocarcinoma and establishment and validation a nomogram: a SEER-based study
    Yiping Hao, Qingqing Liu, Ruowen Li, Zhonghao Mao, Nan Jiang, Bingyu Wang, Wenjing Zhang, Baoxia Cui
    Journal of Obstetrics and Gynaecology.2023;[Epub]     CrossRef
  • Validation of the 2018 FIGO Staging System for Predicting the Prognosis of Patients With Stage IIIC Cervical Cancer
    Xingtao Long, Misi He, Lingling Yang, Dongling Zou, Dong Wang, Yuemei Chen, Qi Zhou
    Clinical Medicine Insights: Oncology.2023;[Epub]     CrossRef
  • Development of novel tracers for sentinel node identification in cervical cancer
    Keisuke Kodama, Chuya Tateishi, Tsuyoshi Oda, Lin Cui, Kazutaka Kuramoto, Hideaki Yahata, Kaoru Okugawa, Shoji Maenohara, Hiroshi Yagi, Masafumi Yasunaga, Ichiro Onoyama, Kazuo Asanoma, Takeshi Mori, Yoshiki Katayama, Kiyoko Kato
    Cancer Science.2023; 114(11): 4216.     CrossRef
  • Preoperative prediction of cervical cancer survival using a high-resolution MRI-based radiomics nomogram
    Jia Li, Hao Zhou, Xiaofei Lu, Yiren Wang, Haowen Pang, Daniel Cesar, Aiai Liu, Ping Zhou
    BMC Medical Imaging.2023;[Epub]     CrossRef
  • Abdominal Radical Hysterectomy as an Alternative Treatment Option for Patients with Cervical Cancer without Access to Radiotherapy Facilities
    Yanna Ye, Zhiqiang Li, Biliang Chen, Shan Kang, Bin Ling, Li Wang, Jilong Yao, Jinghe Lan, Ping Liu, Chunlin Chen
    Clinical and Experimental Obstetrics & Gynecology.2023;[Epub]     CrossRef
  • Canine anal sac gland carcinoma with regional lymph node metastases treated with sacculectomy and lymphadenectomy: Outcome and possible prognostic factors
    Jean‐Benoit Tanis, Angharad B. Simlett‐Moss, Malgorzata Ossowksa, Thomas W. Maddox, James Guillem, Cristobal Lopez‐Jimenez, Gerry Polton, Rachel Burrow, Riccardo Finotello
    Veterinary and Comparative Oncology.2022; 20(1): 276.     CrossRef
  • The prognostic value of the number of positive lymph nodes and the lymph node ratio in early‐stage cervical cancer
    Ester P. Olthof, Constantijne H. Mom, Malou L. H. Snijders, Hans H. B. Wenzel, Jacobus van der Velden, Maaike A. van der Aa
    Acta Obstetricia et Gynecologica Scandinavica.2022; 101(5): 550.     CrossRef
  • Development and Validation of Novel Nomograms to Predict the Overall Survival and Cancer-Specific Survival of Cervical Cancer Patients With Lymph Node Metastasis
    Jianying Yi, Zhili Liu, Lu Wang, Xingxin Zhang, Lili Pi, Chunlei Zhou, Hong Mu
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Treatment Strategies and Prognostic Factors of 2018 FIGO Stage IIIC Cervical Cancer: A Review
    Fengying Qin, Huiting Pang, Tao Yu, Yahong Luo, Yue Dong
    Technology in Cancer Research & Treatment.2022;[Epub]     CrossRef
  • Tumoral Morphologic Features From Cervical Biopsies That Are Predictive of a Negligible Risk for Nodal Metastasis and Tumor Recurrence in Usual-type Cervical Adenocarcinomas
    Yue Wang, Ruby Jean Chang, Rong-Zhen Luo, Jing Yu, Xiaofei Zhang, Xianghong Yang, M.R. Quddus, Li Li, Wentao Yang, Aijun Liu, Qingping Jiang, Ruijiao Zhao, Huiting Zhu, Feng Zhou, Yiying Wang, Xiujie Sheng, Li-Li Liu, Yan-Lin Wen, Natalie Banet, C.J. Sung
    American Journal of Surgical Pathology.2022; 46(5): 713.     CrossRef
  • Significance of the Number and the Location of Metastatic Lymph Nodes in Locally Recurrent or Persistent Cervical Cancer Patients Treated with Salvage Hysterectomy plus Lymphadenectomy
    Seiji Mabuchi, Naoko Komura, Michiko Kodama, Michihide Maeda, Yuri Matsumoto, Shoji Kamiura
    Current Oncology.2022; 29(7): 4856.     CrossRef
  • Development and validation of a nomogram for predicting pelvic lymph node metastasis and prognosis in patients with cervical cancer
    Mengting Wang, Min Ma, Liju Yang, Chengtong Liang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • High expression of PYK2 is associated with poor prognosis and cancer progression in early-stage cervical carcinoma
    Can Zhang, Xinghua Zhu, Yong Li, Jia Shao, Haibo Xu, Lei Chen, Youli Dan, Hua Jin, Aiqin He
    Medicine.2022; 101(41): e31178.     CrossRef
  • Whether individualized dose escalation should be recommended for lymph nodes with different sizes in the definitive radiotherapy of cervical cancer?
    Xiaojuan Lv, Huiting Rao, Tao Feng, Chufan Wu, Hanmei Lou
    Radiation Oncology.2022;[Epub]     CrossRef
  • Prognostic value of lymph node ratio in cervical cancer: A meta-analysis
    Haixia Cui, Yuan Huang, Weibo Wen, Xiangdan Li, Dongyuan Xu, Lan Liu
    Medicine.2022; 101(42): e30745.     CrossRef
  • The Impact of Revised FIGO 2018 Staging System on Survival Outcomes in Patients with Carcinoma Cervix
    Sharanya Sathish, Geeta Acharaya, Kiran Kulkarni, Gayatri Ravikumar
    Indian Journal of Gynecologic Oncology.2022;[Epub]     CrossRef
  • Lymph Node Ratio Is a Strong Prognostic Factor in Patients with Early-Stage Cervical Cancer Undergoing Minimally Invasive Radical Hysterectomy
    Se Ik Kim, Tae Hun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Taek Sang Lee, Hye Won Jeon, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song
    Yonsei Medical Journal.2021; 62(3): 231.     CrossRef
  • Recurrence pattern and prognostic factors for survival in cervical cancer with lymph node metastasis
    Cigdem Kilic, Gunsu Kimyon Comert, Caner Cakir, Dilek Yuksel, Bahadır Codal, Fatih Kilic, Osman Turkmen, Alper Karalok, Ozlem Moraloglu Tekin, Nurettin Boran, Taner Turan
    Journal of Obstetrics and Gynaecology Research.2021; 47(6): 2175.     CrossRef
  • Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis
    Max Peters, Astrid A.C. de Leeuw, Christel N. Nomden, Kari Tanderup, Kathrin Kirchheiner, Jacob C. Lindegaard, Christian Kirisits, Christine Haie-Meder, Alina Sturdza, Lars Fokdal, Umesh Mahantshetty, Peter Hoskin, Barbara Segedin, Kjersti Bruheim, Bhavan
    Radiotherapy and Oncology.2021; 163: 150.     CrossRef
  • Prognostic Value of Lymph Node Characteristics in Patients with Cervical Cancer Treated with Radical Hysterectomy
    Yoon Hee Lee, Gun Oh Chong, Su Jeong Kim, Ja Hyun Hwang, Jong Mi Kim, Nora Jee-Young Park, Dae Gy Hong
    Cancer Management and Research.2021; Volume 13: 8137.     CrossRef
  • The Combination of T Stage and the Number of Pathologic Lymph Nodes Provides Better Prognostic Discrimination in Early-Stage Cervical Cancer With Lymph Node Involvement
    Yongrui Bai, Ling Rong, Bin Hu, Xiumei Ma, Jiahui Wang, Haiyan Chen
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • The prognostic value of lymph node ratio in stage IIIC cervical cancer patients triaged to primary treatment by radical hysterectomy with systematic pelvic and para-aortic lymphadenectomy
    Koray Aslan, Mehmet Mutlu Meydanli, Murat Oz, Yusuf Aytac Tohma, Ali Haberal, Ali Ayhan
    Journal of Gynecologic Oncology.2020;[Epub]     CrossRef
  • Predictive value of preoperative serum squamous cell carcinoma antigen (SCC–Ag) level on tumor recurrence in cervical squamous cell carcinoma patients treated with radical surgery: A single-institution study
    Qinhao Guo, Jun Zhu, Yong Wu, Hao Wen, Lingfang Xia, Xiaohua Wu, Xingzhu Ju
    European Journal of Surgical Oncology.2020; 46(1): 131.     CrossRef
  • Effects of preoperative radiotherapy or chemoradiotherapy on postoperative pathological outcome of cervical cancer——from the large database of 46,313 cases of cervical cancer in China
    Weili Li, Ping Liu, Weidong Zhao, Zhaohong Yin, Zhong Lin, Xiaonong Bin, Jinghe Lang, Chunlin Chen
    European Journal of Surgical Oncology.2020; 46(1): 148.     CrossRef
  • DSG2 expression is correlated with poor prognosis and promotes early-stage cervical cancer
    Shuhang Qin, Yuandong Liao, Qiqiao Du, Wei Wang, Jiaming Huang, Pan Liu, Chunliang Shang, Tianyu Liu, Meng Xia, Shuzhong Yao
    Cancer Cell International.2020;[Epub]     CrossRef
  • Should the Number of Metastatic Pelvic Lymph Nodes Be Integrated into the 2018 Figo Staging Classification of Early Stage Cervical Cancer?
    Luigi Pedone Anchora, Vittoria Carbone, Valerio Gallotta, Francesco Fanfani, Francesco Cosentino, Luigi Carlo Turco, Camilla Fedele, Nicolò Bizzarri, Giovanni Scambia, Gabriella Ferrandina
    Cancers.2020; 12(6): 1552.     CrossRef
  • UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study
    Hideki Matsuoka, Ryusuke Murakami, Kaoru Abiko, Ken Yamaguchi, Akihito Horie, Junzo Hamanishi, Tsukasa Baba, Masaki Mandai
    BMC Cancer.2020;[Epub]     CrossRef
  • Validation of the 2018 FIGO Classification for Cervical Cancer: Lymphovascular Space Invasion Should Be Considered in IB1 Stage
    Vincent Balaya, Benedetta Guani, Laurent Magaud, Hélène Bonsang-Kitzis, Charlotte Ngô, Patrice Mathevet, Fabrice Lécuru
    Cancers.2020; 12(12): 3554.     CrossRef
  • Burden of lymphatic disease predicts efficacy of adjuvant radiation and chemotherapy in FIGO 2018 stage IIICp cervical cancer
    Giorgio Bogani, Daniele Vinti, Ferdinando Murgia, Valentina Chiappa, Umberto Leone Roberti Maggiore, Fabio Martinelli, Antonino Ditto, Francesco Raspagliesi
    International Journal of Gynecological Cancer.2019; 29(9): 1355.     CrossRef
  • Prognostic factors for and pattern of lymph-node involvement in patients with operable cervical cancer
    P. Widschwendter, W. Janni, C. Scholz, A. De Gregorio, N. De Gregorio, T W P Friedl
    Archives of Gynecology and Obstetrics.2019; 300(6): 1709.     CrossRef
  • Postoperative chemotherapy for node-positive cervical cancer: Results of a multicenter phase II trial (JGOG1067)
    Maki Matoda, Nobuhiro Takeshima, Hirofumi Michimae, Takashi Iwata, Harushige Yokota, Yutaka Torii, Yorito Yamamoto, Kazuhiro Takehara, Shin Nishio, Hirokuni Takano, Mika Mizuno, Yoshiyuki Takahashi, Yuji Takei, Tetsuya Hasegawa, Mikio Mikami, Takayuki Eno
    Gynecologic Oncology.2018; 149(3): 513.     CrossRef
  • 10,858 View
  • 340 Download
  • 51 Web of Science
  • 43 Crossref
Close layer
Adjuvant Treatment after Surgery in Stage IIIA Endometrial Adenocarcinoma
Mee Sun Yoon, Seung Jae Huh, Hak Jae Kim, Young Seok Kim, Yong Bae Kim, Joo-Young Kim, Jong-Hoon Lee, Hun Jung Kim, Jihye Cha, Jin Hee Kim, Juree Kim, Won Sup Yoon, Jin Hwa Choi, Mison Chun, Youngmin Choi, Kang Kyoo Lee, Myungsoo Kim, Jae-Uk Jeong, Sei Kyung Chang, Won Park
Cancer Res Treat. 2016;48(3):1074-1083.   Published online October 29, 2015
DOI: https://doi.org/10.4143/crt.2015.356
AbstractAbstract PDFPubReaderePub
Purpose
We evaluated the role of adjuvant therapy in stage IIIA endometrioid adenocarcinoma patients who underwent surgery followed by radiotherapy (RT) alone or chemoradiotherapy (CTRT) according to risk group. Materials and Methods A multicenter retrospective study was conducted including patients with surgical stage IIIA endometrial cancertreated by radical surgery and adjuvant RT or CTRT. Disease-free survival (DFS) and overall survival (OS) were analyzed.
Results
Ninety-three patients with stage IIIA disease were identified. Nineteen patients (20.4%) experienced recurrence, mostly distant metastasis (17.2%). Combined CTRT did not affect DFS (74.1% vs. 82.4%, p=0.130) or OS (96.3% vs. 91.9%, p=0.262) in stage IIIA disease compared with RT alone. Patients with age ≥ 60 years, grade G2/3, and lymphovascular space involvement had a significantly worse DFS and those variables were defined as risk factors. The high-risk group showed a significant reduction in 5-year DFS (≥ 2 risk factors) (49.0% vs. 88.0%, p < 0.001) compared with the low-risk group (< 2). Multivariate analysis confirmed that more than one risk factor was the only predictor of worse DFS (hazard ratio, 5.45; 95% confidence interval, 2.12 to 13.98; p < 0.001). Of patients with no risk factors, a subset treated with RT alone showed an excellent 5-year DFS and OS (93.8% and 100%, respectively). Conclusion We identified a low-risk subset of stage IIIA endometrioid adenocarcinoma patients who might be reasonable candidates for adjuvant RT alone. Further randomized studies are needed to determine which subset might benefit from combined CTRT.

Citations

Citations to this article as recorded by  
  • Practice patterns and survival in FIGO 2009 stage 3B endometrial cancer
    Jessica Jou, Lindsey Charo, Marianne Hom-Tedla, Katherine Coakley, Pratibha Binder, Cheryl Saenz, Ramez N. Eskander, Michael McHale, Steven Plaxe
    Gynecologic Oncology.2021; 163(2): 299.     CrossRef
  • Treatment strategies for endometrial cancer: current practice and perspective
    Yeh C. Lee, Stephanie Lheureux, Amit M. Oza
    Current Opinion in Obstetrics & Gynecology.2017; 29(1): 47.     CrossRef
  • 14,439 View
  • 126 Download
  • 3 Web of Science
  • 2 Crossref
Close layer
A Preliminary Results of a Randomized Trial Comparing Monthly 5-flourouracil and Cisplatin to Weekly Cisplatin Alone Combined with Concurrent Radiotherapy for Locally Advanced Cervical Cancer
Young Seok Kim, Seong Soo Shin, Eun Kyung Choi, Jong Hoon Kim, Seung Do Ahn, Sang-wook Lee, Heon-Jin Park, Young-Tak Kim, Jung-Eun Mok, Joo-Hyun Nam
Cancer Res Treat. 2005;37(1):37-43.   Published online February 28, 2005
DOI: https://doi.org/10.4143/crt.2005.37.1.37
AbstractAbstract PDFPubReaderePub
Purpose

To determine the superior chemotherapeutic regimen between monthly 5-FU plus cisplatin (FP) and weekly cisplatin alone in concurrent chemoradiotherapy for locally advanced cervical cancer, the compliance of treatment, response, survival and toxicities were analyzed between the two arms.

Materials and Methods

Between March 1998 and December 2001, 61 patients with locally advanced cervical cancer (stage IIB through IVA) and negative para-aortic lymph nodes were randomly assigned to either 'monthly FP' (arm I, n=34) or 'weekly cisplatin' (arm II, n=27) with concurrent radiotherapy. The patients of arm I received FP (5-FU 1,000 mg/m2/day + cisplatin 20 mg/m2/day, for 5 days, for 3 cycles at 4 week intervals) and those of arm II received cisplatin (30 mg/m2/day, for 6 cycles at 1 week intervals) with concurrent radiotherapy. The radiotherapy consisted of 41.4~50.4 Gy external beam irradiation in 23~28 fractions to the whole pelvis, with high dose rate brachytherapy delivering a dose of 30~35 Gy in 6~7 fractions to point A. During the brachytherapy, a parametrial boost was delivered. The median follow-up period for survivors was 44 months.

Results

The compliance of treatment in monthly FP weekly cisplatin arms were 62 and 81%, respectively. The complete response rates at 3 months were 96 and 88% in arms I and II, respectively. The 4-year overall survival and disease free survival rates were 64 and 54% in the arm I and 77 and 66% in the arm II, respectively. The incidence of hematologic toxicity more than grade 2 was 29% in the arm I and 15% in the arm II. Only one patient in arm I experienced grade 3 gastrointestinal toxicity. No severe genitourinary toxicity was observed.

Conclusion

No significant difference was observed in the compliance, responses, survival rates and acute toxicities between the two treatment arms. More patients and further follow up will be required.

Citations

Citations to this article as recorded by  
  • American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer
    Jyoti Mayadev, Akila Viswanathan, Yu Liu, Chin-Shang Li, Kevin Albuquerque, Antonio L. Damato, Sushil Beriwal, Beth Erickson
    Brachytherapy.2017; 16(1): 22.     CrossRef
  • Concurrent Weekly Cisplatin Versus Triweekly Cisplatin with Radiotherapy in the Treatment of Cervical Cancer: A Meta-analysis Result
    Yan Hu, Zhi-Qiang Cai, Xiao-Yan Su
    Asian Pacific Journal of Cancer Prevention.2012; 13(9): 4301.     CrossRef
  • Laparoscopy-Assisted Intracavitary Radiotherapy Tandem Placement for Patients With Cervical Cancer
    Myong Cheol Lim, Dae Chul Jung, Joo-Young Kim, Sang-Yoon Park
    International Journal of Gynecological Cancer.2009; 19(6): 1125.     CrossRef
  • Adoptive Transfer of Human Papillomavirus E7-specific CTL Enhances Tumor Chemoresponse Through the Perforin/Granzyme-mediated Pathway
    Jeong-Im Sin, Jung-Min Kim, Sung Hwa Bae, In Hee Lee, Jong Sup Park, Hun Mo Ryoo
    Molecular Therapy.2009; 17(5): 906.     CrossRef
  • 10,038 View
  • 56 Download
  • 4 Crossref
Close layer
Ependymoma: a Retrospective Analysis of 25 Cases
Young Seok Kim, Seung Do Ahn, Eun Kyung Choi, Jong Hoon Kim, Sang Wook Lee, Young Ju Noh, Chang Jin Kim, Jeong Hoon Kim, Byung Duk Kwun
Cancer Res Treat. 2002;34(6):450-456.   Published online December 31, 2002
DOI: https://doi.org/10.4143/crt.2002.34.6.450
AbstractAbstract PDF
PURPOSE
We evaluated the patterns of failure, survival rate, prognostic factors and treatment related complication in postoperative radiation treatment of patients with ependymoma.
MATERIALS AND METHODS
We retrospectively analyzed 25 patients with histologically confirmed ependymoma treated between Jun. 1990 and Jun. 2001 with postoperative radiotherapy at Asan Medical Center. The study group comprised of 16 men and 9 women, with a median age of 23 years; including 6 supratentorial, 15 infratentorial and 4 spinal cord lesions. The extents of resection were ranked as either: gross total, near total, subtotal, partial resection or biopsy, with these types of surgical resection being performed in 13, 3, 6, 1 and 2 patients, respectively. Twelve of the patients had low grade ependymoma, and the other 13 a high grade tumor. The postoperative irradiation was administered using 4 MV or 6 MV photons, up to median dose of 55.0 Gy (range, 45.0~59.4 Gy), with the radiation field encompassing the preoperative tumor volume plus a 2 cm margin. Only 8 of the patients received either pre- or postoperative chemotherapy. The median follow-up period of survivors was 43 months.
RESULTS
Ten of the 25 patients (40%) developed a recurrence, and 5 died. Of the 10 recurred patients, 6 showed an in-field recurrence, and one developed both an in-field and an out of field recurrence. The remaining 3 patients showed an out of field recurrence, including one case with a leptomeningeal recurrence. The 5-year overall survival, and progression-free, survival rates were 74.0 and 56.1%, respectively. The histological grades were statistically significant prognostic factors of the overall and progression-free survival rates. There were no significant treatment related complications, with the exception of one case of panhypopituitarism, which occurred 30 months after completion of the radiotherapy.
CONCLUSION
The main pattern of recurrence was due to local failure. In order to improve the local control, and to reduce complications, advanced radiation treatment techniques, such as 3 dimensional radiotherapy, may be needed.

Citations

Citations to this article as recorded by  
  • Clinical outcomes of radiotherapy for spinal cord ependymoma with adverse prognostic features: a single-center study
    Hwa Kyung Byun, Seong Yi, Hong In Yoon, Se Hoon Kim, Jaeho Cho, Chang-Ok Suh
    Journal of Neuro-Oncology.2018; 140(3): 649.     CrossRef
  • 4,586 View
  • 22 Download
  • 1 Crossref
Close layer
Concurrent Chemoradiotherapy in Locally Advanced Carcinoma of the Uterine Cervix Preliminary Results of Phases III Prospective Randomized Trial
Young Seok Kim, Eun Kyung Choi, Jong Hoon Kim, Seung Do Ahn, Sang Wook Lee, Jong Hyeok Kim, Yong Man Kim, Young Tak Kim, Jung Eun Mok, Joo Hyun Nam
Cancer Res Treat. 2002;34(3):191-197.   Published online June 30, 2002
DOI: https://doi.org/10.4143/crt.2002.34.3.191
AbstractAbstract PDF
PURPOSE
A prospective, randomized phase III, clinical trial was performed to assess treatment related acute toxicity, early response and survival difference, between a monthly 5-FU cisplatin, and a weekly cisplatin group alone, for concurrent chemoradiotherapy in the locally advanced uterine cervical carcinoma patients. MATERIALS AND METGODS: Between March 1998 and March 2000, 35 patients, with locally advanced (FIGO stage IIB to IVA) cervical carcinoma, were studied, but 5 patients were excluded inform the analysis due to their refusal of treatment. The patients were randomly assigned to 'monthly 5-FU cisplatin' (arm I), or 'weekly cisplatin' (arm II), groups. The patients of arm I received 5-FU cisplatin (5-FU 1,000 mg/m2/day cisplatin 20 mg/m2/day, IV continuous infusion, for 5 days, 3 cycles with 4-week intervals) with radiation therapy. Those of arm II received only cisplatin (cisplatin 30 mg/m2/day, IV bolus, 6 cycles with 1-week intervals) with radiation therapy. The radiation therapy consisted of external beam irradiation of 41.4~50.4 Gy/23~28 fractions, and high dose rate intracavitary treatments, delivering a dose of 30~35 Gy to point A in 6~7 fractions. During intracavitary radiation, a parametrial boost was delivered for a point B dose of 60 Gy in the non-thickened side, and 65 Gy in the thickened side. Treatment related acute toxicities were assessed using Radiation Therapy Oncology Group (RTOG) acute morbidity scoring criteria. The response to treatment, and survival, were analyzed. The median follow-up period was 19 months.
RESULTS
The FIGO stage distributions of arm I (n=16) and arm II (n=14) were as follows; IIB 10, IIIA 1, IIIB 4, IVA 1 in arm I, 12, 0, 1 and 1 in arm II respectively. The compliance of both arms were 80.0% and 93.3%, respectively (p=0.37). During radiation therapy, the incidences of leukopenia, greater than RTOG grade 2, were 25.0%, 14.3%, respectively. There were no patients with gastrointestinal or genitourinary toxicity greater than RTOG grade 2. The complete response rates at 3 months, following radiation therapy, were 87.5% and 92.9% respectively. Two-year disease free survival rates were 81.3%, 85.7%, respectively, for each arms.
CONCLUSION
There was no significant difference in response to treatment, or patterns of failure, between the monthly FP and weekly cisplatin arms. Although there were no statistically significant differences, the patients of the weekly cisplatin arm had better compliance. More patients, and a longer follow up, are needed for improved evaluation of the regimen.
  • 4,058 View
  • 31 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP